Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500251 · ClinicalTrials.gov registry record · Phase 1
Belimumab Impacting Transplant Eligibility
A Phase 1 study of Renal Transplant Rejection, sponsored by E. Steve Woodle.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT02500251: Completed Phase 1 study of Renal Transplant Rejection, sponsored by E. Steve Woodle.
NCT02500251 is a Phase 1 study of Renal Transplant Rejection that has completed, run by E. Steve Woodle. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02500251, a Phase 1 study of Renal Transplant Rejection, has completed, sponsored by E. Steve Woodle.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a prospective, open label, phase I/II pilot study.
Primary Outcome
Maximal percent reduction in immunodominant DSA (iDSA) \[highest titer DSA (MFI)\] and/or immunodominant antibody (iAb) from pre-treatment to Day 151.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bortezomib
- DRUG belimumab
- DRUG Plasmapheresis
Study Locations (2)
Ohio
- The Christ Hospital - Cincinnati
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
What the finished NCT02500251 record still lists
NCT02500251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Renal Transplant Rejection appearing as the primary indexed condition, and to 4 interventions - of which Rituximab is the first listed.
NCT02500251 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02500251 about?
NCT02500251 is a clinical study titled "Belimumab Impacting Transplant Eligibility". This study is a prospective, open label, phase I/II pilot study.
What is the current status of trial NCT02500251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-06. Estimated completion is 2018-08.
What conditions does trial NCT02500251 study?
This clinical trial studies the following conditions: Renal Transplant Rejection.
What interventions are being tested in trial NCT02500251?
The interventions under investigation include: Rituximab (DRUG), Bortezomib (DRUG), belimumab (DRUG), Plasmapheresis (DRUG).
Who is sponsoring clinical trial NCT02500251?
This trial is sponsored by E. Steve Woodle, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02500251 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02500251's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia